Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XILO-FIST: Xanthine oxidase inhibition after ischaemic stroke and TIA
2013-004235-77Phase 3Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of allopurinol in ischemic stroke and transient ischaemic attack (TIA) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: WMH progression rate over 2 years. Status: unknown.
02
Drugs
allopurinol
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on 2013-004235-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004235-77.